Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Conditions
Brief summary
This is a multicenter, open-label, single-arm, prospective Phase II clinical trial. The study enrolls patients with extrahepatic cholangiocarcinoma or gallbladder carcinoma who have undergone curative resection and harbor high-risk recurrence factors, including: 1) narrow resection margin (including R1 resection); 2) positive circumferential resection margin; 3) T stage ≥ T3-4; 4）positive regional lymph nodes. All patients will receive postoperative concurrent chemoradiotherapy (CCRT) with intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT). The high-risk volumes of the primary tumor bed and metastatic lymph node beds will be irradiated to 48-60 Gy in 20-25 fractions. Retroperitoneal and intra-abdominal lymph nodes will receive 50-57.5 Gy in 20-25 fractions, and lymphatic drainage regions will be treated to 40-45 Gy in 20-25 fractions. During radiotherapy, concurrent oral capecitabine will be administered at a dose of 1,600 mg/m² on Days 1-14, every 21 days for 2 cycles. Following the completion of radiotherapy, maintenance oral capecitabine will be continued at 2,000 mg/m² on Days 1-14, every 21 days for 6 cycles. For patients intolerant to capecitabine, S-1 will be substituted: concurrent S-1 40-50 mg twice daily on Days 1-28, every 42 days for 1 cycle, followed by maintenance S-1 40-60 mg twice daily on Days 1-28, every 42 days for 3 cycles. The primary study endpoint is the 2-year recurrence-free survival (RFS) rate. Secondary study endpoints include the 2-year overall survival (OS) rate, locoregional control rate, and incidence of grade ≥3 adverse events. A total of 92 patients are planned for enrollment in this trial.
Interventions
RADIATIONPostoperative radiotherapy
All patients will receive postoperative concurrent chemoradiotherapy with IMRT or VMAT. The high-risk volumes of the primary tumor bed and metastatic lymph node beds will be irradiated to 48-60 Gy in 20-25 fractions. Retroperitoneal and intra-abdominal lymph nodes will receive 50-57.5 Gy in 20-25 fractions, and lymphatic drainage regions will be treated to 40-45 Gy in 20-25 fractions.
DRUGCapecitabine or S-1
During radiotherapy, concurrent oral capecitabine will be administered at a dose of 1,600 mg/m² on Days 1-14, every 21 days for 2 cycles. Following the completion of radiotherapy, maintenance oral capecitabine will be continued at 2,000 mg/m² on Days 1-14, every 21 days for 6 cycles. For patients intolerant to capecitabine, S-1 will be substituted: concurrent S-1 40-50 mg twice daily on Days 1-28, every 42 days for 1 cycle, followed by maintenance S-1 40-60 mg twice daily on Days 1-28, every 42 days for 3 cycles.
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Aged 18-80 years * Underwent curative resection for newly diagnosed disease, with postoperative pathology confirming extrahepatic cholangiocarcinoma or gallbladder adenocarcinoma * Postoperative pathology with ≥1 high-risk factor for recurrence 1. Narrow resection margin (\<1 cm), including R1 resection 2. Positive circumferential resection margin 3. T stage ≥ T3-4 4. Positive regional lymph nodes * Postoperative liver function: Child-Pugh grade A5-B7 * No recurrence or metastasis before postoperative radiotherapy * ECOG performance status 0-2 * Expected survival \>3 months * Routine blood tests: Neutrophils ≥1.0×10⁹/L, hemoglobin ≥80 g/L, platelets ≥100×10⁹/L * Liver function: Total bilirubin \<1.5×upper limit of normal (ULN), plus one of the following: 1. ALT and AST ≤2.5×ULN 2. ALT ≤1.5×ULN and AST ≤6×ULN (excluding AST elevation due to myocardial infarction) * Renal function: Creatinine and blood urea nitrogen ≤2.5×ULN * Voluntary participation and signed informed consent
Exclusion criteria
* History of other malignant tumors (except papillary thyroid carcinoma, basal cell carcinoma of the skin, and cervical carcinoma in situ) * Severe comorbidities (e.g., myocardial infarction, arrhythmia, psychiatric disorders) * Prior abdominal radiotherapy * Post-organ transplantation * Symptomatic moderate-severe ascites within 4 months postoperatively * ≥4 months since surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year recurrence-free survival (RFS) rate | From completion of radiotherapy until 2 years after radiotherapy |
Secondary
| Measure | Time frame |
|---|---|
| 2-year overall survival (OS) rate | From completion of radiotherapy until 2 years after radiotherapy |
| Locoregional control rate | From completion of radiotherapy until 2 years after radiotherapy |
| Incidence of grade ≥3 treatment-related adverse events | From initiation of radiotherapy until 3 months after radiotherapy |
Countries
China
Contacts
CONTACTBo Chen, MD
Outcome results
None listed